Gene remedy builders depend on hollowed-out viruses to shuttle DNA into the physique, the place it might deal with or doubtlessly even remedy a genetic illness. However many of the dozens of corporations within the discipline use simply two sorts of viruses for his or her DNA supply. Carbon Biosciences hopes to broaden that toolbox.
The Lexington, Mass., startup launched Tuesday with $38 million in collection A financing to create a brand new class of gene therapies primarily based on parvoviruses — a big household of viruses greatest identified for infecting canines, however comprised of many little-studied viruses that may infect people and different animals, too.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
